Drug Trial News

RSS

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments.

28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Earlier antiretroviral treatment benefits HIV-infected individuals

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count--a key measure of immune system health--is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.

28 May 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

28 May 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

Soy supplement does not improve lung function, clinical outcomes in patients with asthma

Although some data have suggested that supplementation with soy isoflavone may be an effective treatment for patients with poor asthma control, a randomized trial that included nearly 400 children and adults found that use of the supplement did not result in improved lung function or clinical outcomes, including asthma symptoms and episodes of poor asthma control, according to a study in the May 26 issue of JAMA.

27 May 2015

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan.

27 May 2015

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.

27 May 2015

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and arterial disease, today reported that it has initiated an open-label, multicenter Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E."

26 May 2015

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%.

22 May 2015

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million.

22 May 2015

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

21 May 2015

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.

21 May 2015

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Laboratories, Inc., a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone.

20 May 2015

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases...

20 May 2015

Drug Trial News

Green tea components may help prevent prostate cancer development in at-risk men

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Earlier antiretroviral treatment benefits HIV-infected individuals

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Soy supplement does not improve lung function, clinical outcomes in patients with asthma

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News